Yes, maraviroc was able to enroll 1000+ patients, and it was MDR3 class I believe like IZ. I believe part of the issue was the restrictions, maybe not being exposed to ccr5 inhibitor before. People on maraviroc that developed resistance could have been put on leronlimab in the trial. Not sure, but these other ccr5 mdr trials found 500 to 1000 patients. Maybe they had a larger number of enrollment centers or other less restrictions in other areas beside mdr3, not sure.